Loading...
XPARVETO
Market cap940mUSD
Dec 23, Last price  
76.40EUR
1D
2.83%
1Q
-10.43%
Jan 2017
67.80%
IPO
232.17%
Name

Vétoquinol

Chart & Performance

D1W1MN
XPAR:VETO chart
P/E
16.27
P/S
1.71
EPS
4.70
Div Yield, %
1.05%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.54%
Revenues
529m
-1.95%
196,617,000211,591,000233,364,000234,395,000257,057,000282,041,000284,137,000298,293,000299,727,000315,298,000342,612,000350,354,000352,173,000367,941,000395,990,000427,467,000521,272,000539,779,000529,270,999
Net income
56m
+15.76%
12,440,72015,824,00018,642,00018,564,00018,207,00022,255,00022,695,00022,569,00023,580,00025,766,00024,156,00027,827,00034,831,00036,259,00028,589,00019,221,00062,861,00047,995,00055,560,000
CFO
89m
+43.27%
30,014,00023,356,00037,215,00021,903,00040,046,00034,360,00029,992,00034,209,00028,106,00041,298,00038,897,00043,205,00041,225,00037,884,00052,024,00092,012,00089,167,00062,392,00089,391,000
Dividend
Jun 04, 20240.85 EUR/sh
Earnings
Mar 18, 2025

Profile

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
URL
https://www.vetoquinol.com/fr
IPO date
Nov 16, 2006
Employees
2,455
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
529,271
-1.95%
539,779
3.55%
521,272
21.94%
Cost of revenue
460,546
487,931
478,377
Unusual Expense (Income)
NOPBT
68,725
51,848
42,895
NOPBT Margin
12.98%
9.61%
8.23%
Operating Taxes
21,340
20,649
20,209
Tax Rate
31.05%
39.83%
47.11%
NOPAT
47,385
31,199
22,686
Net income
55,560
15.76%
47,995
-23.65%
62,861
227.04%
Dividends
(9,465)
(9,465)
(5,914)
Dividend yield
0.78%
0.91%
0.38%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,965
7,860
8,316
Long-term debt
24,132
9,561
7,067
Deferred revenue
9,382
6,880
Other long-term liabilities
8,901
9,220
11,055
Net debt
(116,858)
(77,731)
(55,684)
Cash flow
Cash from operating activities
89,391
62,392
89,167
CAPEX
(14,896)
(22,497)
(32,403)
Cash from investing activities
(18,881)
(21,518)
(33,445)
Cash from financing activities
(15,497)
(15,600)
(120,305)
FCF
(2,705)
(6,598)
20,506
Balance
Cash
147,464
93,708
68,999
Long term investments
1,491
1,444
2,068
Excess cash
122,491
68,163
45,003
Stockholders' equity
485,984
491,532
463,089
Invested Capital
431,148
437,563
415,513
ROIC
10.91%
7.31%
5.57%
ROCE
12.25%
10.09%
9.15%
EV
Common stock shares outstanding
11,833
11,832
11,828
Price
102.40
16.89%
87.60
-33.64%
132.00
57.89%
Market cap
1,211,649
16.90%
1,036,447
-33.61%
1,561,265
57.92%
EV
1,094,888
958,808
1,505,672
EBITDA
103,227
83,398
75,767
EV/EBITDA
10.61
11.50
19.87
Interest
1,137
3,261
1,036
Interest/NOPBT
1.65%
6.29%
2.42%